title: Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents.
abstract: Posttransplant diabetes mellitus (PTDM) is a disturbing side effect of immunosuppression. The aim of this study was to evaluate the effect of different immunosuppressive agents on the development of PTDM in renal transplant recipients (KTx). The incidence of PTDM was evaluated in 538 consecutive KTx. Baseline immunosuppression was azathioprine (AZA), cyclosporine (CSA), or tacrolimus (TAC), or sirolimus in combination with calcineurin inhibitors (SIR). All patients received steroids for both induction and maintenance therapy during the first 6 months posttransplantation. Mean follow-up after KTx was 73 +/- 53.5 months (range 6 months to 16 years). PTDM was defined as two consecutive blood glucose determinations above 126 mg/dL. Thirty-six of 538 (6.7%) recipients experienced PTDM, 31 of whom required insulin treatment and five oral antidiabetic medications. PTDM occurred at 25.3 +/- 38 months posttransplantation in 4.8% of KTx treated with AZA, 4.8% of CSA, 6.5% of KTx treated with TAC and 12.5% of KTx treated with SIR. The time of onset of PTDM was significantly shorter (P =.003) among TAC (2.1 +/- 1.7 months posttransplantation) versus CSA (27.8 +/- 34 months). PTDM disappeared in 6 of 36 patients. We conclude that with current levels of immunosuppression, there is no difference in the incidence of PTDM between TAC- and CSA-treated KTx.
authors.affiliation: Clinica Chirurgica, Catholic University, Rome, Italy. jromagnoli@unicatt.it
authors.forename: J
authors.initials: J
authors.lastname: Romagnoli
authors.forename: F
authors.initials: F
authors.lastname: Citterio
authors.forename: P
authors.initials: P
authors.lastname: Violi
authors.forename: G
authors.initials: G
authors.lastname: Nanni
authors.forename: M
authors.initials: M
authors.lastname: Castagneto
mesh_terms: D000284:Administration, Oral; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D007328:Insulin / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D007328:Insulin